Experience with bisphosphonates in osteogenesis imperfecta

Pediatrics

Volumn 119, Issue SUPPL. 2, 2007, Pages

  Glorieux, Francis H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bisphosphonate; Osteogenesis imperfecta; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

BONE MASS; BONE PAIN; BONE REMODELING; BONE TURNOVER; CELL ACTIVITY; CONFERENCE PAPER; ENERGY; FRACTURE; HUMAN; MOBILIZATION; MORPHOMETRICS; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOTOMY; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TRABECULAR BONE; WOUND HEALING;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; OSTEOGENESIS IMPERFECTA; TREATMENT OUTCOME;

EID: 33947168658     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2023I     Document Type: Conference Paper

References (20)

1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377-1385
2. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26:581-589
3. Glorieux FH, Bishop NJ, Plotkin, H, Chabot G, Lanoue G, Travers R. Cyclical administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952
4. Montpetit K, Plotkin H, Rauch F, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics. 2003;111(5). Available at: www.pediatrics.org/cgi/content/full/111/5/e601
5. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18:610-614
6. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006;39:901-906
7. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846-1850
8. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment in osteogenesis imperfecta. Arch Dis Child. 2002;86:356-364
9. Zacharin M, Batemen J. Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment. J Pediatr Endocrinol Metab. 2002;15:163-174
10. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr. 2003;92:452-455
11. Glorieux FH, Rauch F, Ward LM, et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. J Bone Miner Res. 2004;19:S12
12. Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr. 2006;148:456-460
13. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111:1030-1036
14. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110:1293-1299
15. Rauch R, Travers R, Munns CF, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004;19:1191-1193
16. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779-1786
17. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687-694
18. Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int. 1999;64:185-190
19. Weber M, Roschger P, Fratzl-Zelman N, et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone. 2006;39:616-622
20. Munns CF, Rauch F, Ward LM, Glorieux FH. Maternal and fetal outcome following long term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004;19:1742-1745